Digoxin in the management of cardiovascular disorders.
Gheorghiade
Mihai
M
Division of Cardiology, Northwestern University Feinberg School of Medicine, Galter 10-240, 201 East Huron St, Chicago, Ill 60611-2908, USA. m-gheorghiade@northwestern.edu
Adams
Kirkwood F
KF
Colucci
Wilson S
WS
D000368:Aged; D001281:Atrial Fibrillation / Q000188:drug therapy / Q000503:physiopathology; D001682:Biological Availability; D020013:Calcium Signaling / Q000187:drug effects; D002316:Cardiotonic Agents / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy*; D004077:Digoxin / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use*; D004347:Drug Interactions; D005260:Female; D006333:Heart Failure / Q000188:drug therapy / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D008297:Male; D008875:Middle Aged; D009200:Myocardial Contraction / Q000187:drug effects; D010275:Parasympathetic Nervous System / Q000187:drug effects; D010277:Parasympathomimetics / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D016032:Randomized Controlled Trials as Topic; D000254:Sodium-Potassium-Exchanging ATPase / Q000037:antagonists & inhibitors
D002316:Cardiotonic Agents; D010277:Parasympathomimetics; C028996:cardiac glycoside receptors; C027082:digitalis receptor; D004077:Digoxin; D000254:Sodium-Potassium-Exchanging ATPase